TheraRadar
← Back
Data updated: May 24, 2026

ARGENX BV

Biotech
NeurologyOphthalmologyMetabolic Execution: Fair

ARGENX BV is a biotechnology company focused on Neurology, Ophthalmology, Metabolic. Key products include VYVGART.

2021
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Biologics
Novel Drugs (2021):
1 Novel Approvals 1 First-in-Class 1 Orphan Drug

ARGENX BV at a Glance

  • Fast trial execution (23 months median completion)

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

VYVGART HYTRULO
Immunology

Myasthenia Gravis

FcRn Approved 2023
VYVGART
Immunology

Generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive

FcRn Approved 2021

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

No recent approvals

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Neurology 51%
1 drugs Phase 3: 3 Phase 2: 4 Phase 1: 1
Ophthalmology 23%
0 drugs Phase 3: 3
Metabolic 15%
0 drugs Phase 3: 2
Immunology 8%
0 drugs Phase 2: 2
Oncology 4%
0 drugs Phase 1: 2

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

8
Phase 3
6
Phase 2
3
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • VYVGART HYTRULO leads revenue
  • • 2 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Neurology pipeline focus
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 9/23 completed
  • • Speed: 23 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges